UroGen Pharma (URGN) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Join SI Premium – FREE
UroGen Pharma (NASDAQ: URGN) reported Q2 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $72.5 million versus the consensus estimate of $62.16 million.
For earnings history and earnings-related data on UroGen Pharma (URGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westport Fuel Systems (WPRT) Misses Q2 EPS by 64c
- RideNow Group, Inc. (RDNW) Tops Q2 EPS by 4c
- Snail, Inc. (SNAL) Reports Q3 Loss of $0.36
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
